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Abstract
Background: The fixed dose antimalarial combination of dihydroartemisinin-piperaquine (DP) is a promising new
artemisinin-based combination therapy (ACT). We present an individual patient data analysis of efficacy and tolerability in
acute uncomplicated falciparum malaria, from seven published randomized clinical trials conducted in Africa and South East
Asia using a predefined in-vivo protocol. Comparator drugs were mefloquine-artesunate (MAS3) in Thailand, Myanmar, Laos
and Cambodia; artemether-lumefantrine in Uganda; and amodiaquine+sulfadoxine-pyrimethamine and artesunate+amo-
diaquine in Rwanda.
Methods and Findings: In total 3,547 patients were enrolled: 1,814 patients (32% children under five years) received DP and
1,733 received a comparator antimalarial at 12 different sites and were followed for 28–63 days. There was no significant
heterogeneity between trials. DP was well tolerated with 1.7% early vomiting. There were less adverse events with DP in
children and adults compared to MAS3 except for diarrhea; ORs (95%CI) 2.74 (2.13 to 3.51) and 3.11 (2.31 to 4.18),
respectively. DP treatment resulted in a rapid clearance of fever and parasitaemia. The PCR genotype corrected efficacy at
Day 28 of DP assessed by survival analysis was 98.7% (95%CI 97.6–99.8). DP was superior to the comparator drugs in
protecting against both P.falciparum recurrence and recrudescence (P = 0.001, weighted by site). There was no difference
between DP and MAS3 in treating P. vivax co-infections and in suppressing the first relapse (median interval to P. vivax
recurrence: 6 weeks). Children under 5 y were at higher risk of recurrence for both infections. The proportion of patients
developing gametocytaemia (P = 0.002, weighted by site) and the subsequent gametocyte carriage rates were higher with
DP (11/1000 person gametocyte week, PGW) than MAS3 (6/1000 PGW, P = 0.001, weighted by site).
Conclusions: DP proved a safe, well tolerated, and highly effective treatment of P.falciparum malaria in Asia and Africa, but
the effect on gametocyte carriage was inferior to that of MAS3.
Citation: Zwang J, Ashley EA, Karema C, D’Alessandro U, Smithuis F, et al. (2009) Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A
Prospective Multi-Centre Individual Patient Data Analysis. PLoS ONE 4(7): e6358. doi:10.1371/journal.pone.0006358
Editor: David Joseph Diemert, Sabin Vaccine Institute, United States of America
Received January 30, 2009; Accepted June 5, 2009; Published July 29, 2009
Copyright:  2009 Zwang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JZ received grant support from Holley-Pharm, one of the manufacturers of dihydroartemisinin-piperaquine, to conduct this analysis. FN and EAA have
received grant support from the Medicines for Malaria Venture and Holley-Pharm to conduct clinical studies with dihydroartemisinin-piperaquine. The funders
had no role in study design of the trials or in the design of the analysis, data collection, decision to publish, or preparation of the manuscript. The Shoklo Malaria
Research Unit and Laos Unit are part of Mahidol Oxford Research Unit (MORU), funded by the Wellcome Trust of Great Britain.
Competing Interests: NJW is co-chairman of the World Health Organisation malaria treatment guidelines committee. The authors have no other conflicts of
interest.
* E-mail: SMRU@tropmedres.ac
Introduction
Over 80 countries worldwide have now implemented WHO
recommendations to use artemisinin-based combination therapy
(ACT) as first-line treatment of Plasmodium falciparum malaria [1,2].
Dihydroartemisinin-piperaquine (DP) is a fixed dose co-formulat-
ed ACT used increasingly in South East Asia, although it is not yet
registered by most national drug authorities. Most experience of
the use of DP comes from Vietnam, where it is the recommended
first-line treatment. The bisquinoline compound piperaquine as a
monotherapy was used extensively in China where it replaced
chloroquine as the first-line treatment of falciparum and vivax
malaria. Between 1976 and 1994 over 300 tons of piperaquine
were used in China in antimalarial prophylaxis and treatment.
The first combination of DHA and piperaquine (China-Vietnam
8, CV8), also included primaquine and trimethoprim and was first
evaluated in Vietnam in 1990 [3]. CV8 was effective, and became
part of national treatment policy but, because of primaquine
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toxicity concerns and uncertainty whether trimethoprim contrib-
uted to treatment efficacy, these two component drugs were
eventually removed. The new two drugs combination became first
line treatment in Vietnam in 2007.
Piperaquine has a terminal half-life of several weeks [4]. It is
highly active against chloroquine-resistant Plasmodium falciparum,
and vivax [5]. Dihydroartemisinin (DHA) is the active metabolite of
artesunate and artemether. Recently, several clinical trials have
been carried out to study the safety and efficacy of DP for the
treatment of P.falciparum malaria. The randomized trials included
in this individual patient data analysis [6–12] were conducted
between October 2003 and June 2006 using a prospectively
predefined protocol with a follow-up of at least 28 days and use of
PCR parasite genotyping to distinguish new infections from
recrudescences.
Methods
The trials were conducted in North-western Thailand,
Rakhine state, Myanmar, Southern Laos, and Western Cambo-
dia, where mefloquine combined with a three day course of
artesunate (MAS3) was the comparator drug, in Uganda where
artemether-lumefantrine (AL) was the comparator, and in
Rwanda, where artesunate+amodiaquine (AS+AQ) and a non-
ACT group amodiaquine+sulfadoxine-pyrimethamine (AQ+SP)
were the comparator antimalarial drugs. In Rwanda, following
high levels of chloroquine (CQ) resistance, the combination
AQ+SP was adopted as the first-line anti-malaria treatment in
2001. However, AQ+SP has always been considered an interim
strategy and different artemisinin-based combination treatments
(ACT) have been tested in the past few years as possible
alternatives.
Patients presenting with acute uncomplicated falciparum
malaria were recruited into the treatment studies provided they
gave fully informed consent. Eligible patients were 12 to 59
months old patients weighing more than 10 kg in Rwanda, 6
months to 10 years old, weight .5 kg in Uganda, and all patients
between 1 and 65 years in Myanmar, Laos, Cambodia, and
Thailand. Only uncomplicated cases of P.falciparum monoinfec-
tions were included in Laos, Rwanda, and Uganda, while in
Cambodia, Thailand and Myanmar patients with mixed (P.falci-
parum and P. vivax) infections were included. Studies excluded
pregnant or breastfeeding women, patients with HIV-AIDS or
severe malaria. Malaria on admission and reappearance were
confirmed by microscopy examination of blood smears. All sites
screened actively for adverse events until Day 28.
Study design and treatment regimens
Trials were open label randomized comparative studies.
Lengths of follow-up varied from 28 days in Rwanda, to 42 days
in Laos, Myanmar, Uganda, and 63 days in Cambodia and
Thailand. Patients received a total dose of approximately 7 mg/kg
bw dihydroartemisinin and 56 mg/kg bw piperaquine divided into
3 daily doses, except in Cambodia and in the first trial in Thailand
in which an earlier dose regimen was used where the same total
dose was divided into 4 doses given at 0, 8, 24 and 48 h. One
tablet of DP (ArtekinH, Holleykin Pharmaceutical Co., and in
Uganda: Duo-cotecxinH, HolleyPharm) contained 40 mg of
dihydroartemisinin and 320 mg of piperaquine phosphate.
Comparator drug doses were MAS3 3 days: artesunate 4 mg/
kg/day, and mefloquine 8 mg/kg/day, or AQ+SP: AQ 10 mg/
kg/day for 3 days and SP 25 mg/kg of sulfadoxine and 1.25 mg/
kg of pyrimethamine the first day or AS+AQ 3 days: artesunate
4 mg/kg/day, and amodiaquine 10 mg/kg/day, and AL, 20 mg
artemether/120 mg lumefantrine tablets according to weight as
one (5–14 kg), two (15–24 kg), three (25–34 kg), or four ($35 kg)
tablets given twice daily for 3 days.
Drug administration was observed directly by study investiga-
tors, except for one arm in Myanmar where effectiveness was
assessed [8]. The doses were crushed and mixed with water and
given in a syringe or on a spoon for children unable to swallow
tablets, and if vomiting occurred within one hour of dosing
(defined as early vomiting), the medication was re-administered.
Drugs were given with food in Cambodia, and Laos, and a glass of
milk in Uganda. In Myanmar, Thailand, and Rwanda no food
was given.
Reappearance of falciparum malaria during the follow-up
period
Polymerase chain reaction (PCR) parasite genotyping was
performed on paired samples for parasite genotyping to distinguish
between new infections and recrudescent cases. Allelic variation
within MSP1, MSP2, and GLURP was used in Asia as described
previously [13]. In Rwanda, DNA was purified [14] and two
polymorphic markers MSP1 and MSP2 were analyzed [15]. In
Uganda where transmission intensity is very high, selected regions
of MSP1 and MSP2 and 4 microsatellite markers were amplified
using PCR and characterized based on sequence and size
polymorphisms identified by gel electrophoresis [16].
Ethical Approval
The clinical trials from each country were approved by
appropriate authorities. The Thai studies were approved by the
Faculty of Tropical Medicine, Mahidol University Ethical
Committee (Bangkok, Thailand). Approval for the Laos study
was granted by the Ethical Committee of the Faculty of Medical
Sciences, National University of Laos; both of these studies
were also approved by the Oxford Tropical Research Ethics
Committee (OXTREC), University of Oxford, UK. The
protocol for the trial in Myanmar was approved by the Myanmar
Department of Health and by the Me´decins Sans Frontie`res
(MSF) Ethical Review Board. In Rwanda, the study was reviewed
and approved by the Ministry of Health of Rwanda and by the
Ethical Committee of the Prince Leopold Institute of Tropical
Medicine, Antwerp, Belgium. The Cambodian study received
ethical clearance from the Cambodian National Ethical Review
Committee (Ministry of Health, Cambodia), and the MSF
Ethical Review Board. In Uganda, approval came from the
Makerere University Research and Ethics Committee, the
Uganda National Council of Science and Technology, and the
University of California, San Francisco Committee for Human
Research.
Data pooling
The databases of randomized controlled trials were sent by the
investigators. The following aspects of the quality of trial
methodology were evaluated: generation of the allocation
sequence, adequacy of concealment of the allocation of treatment,
degree of blinding, and completeness of follow-up. Generation of
the allocation sequence and allocation concealment was classified
as adequate, inadequate, or unclear [17].
Blinding was classified as open, single or double. The
proportion of patients lost to follow-up (regardless of failures)
was computed and considered acceptable if ,10% within 28 days.
Other markers of quality assessed were whether a sample size was
determined using power calculations and whether an intention-to-
treat (ITT) analysis could be computed.
Dihydroartemisinin-Piperaquine
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Study endpoints and statistical analysis
The analysis was by modified intention-to-treat where patients
who did not complete the study were censored on their last day of
follow-up, but they were not regarded as a failure as in a ‘‘pure’’
ITT analysis.
The primary endpoint was the treatment efficacy by Day 28.
Patients lost to follow-up (or missing a weekly visit) or with a new P.
falciparum infection were censored for the primary outcome at the time
they were last seen. All studies followed patients for at least 28 days
and the primary endpoint was defined prospectively as the
parasitological treatment failure (PCR confirmed: recrudescence,
and PCR not corrected: recurrence). Treatment failure was
considered as the sum of early and late treatment failures, as defined
by the WHO [1] as one of the following: (i) danger signs, death, or
severe malaria at Days 1, 2 or 3 with parasitaemia; (ii) parasite density
at Day 2.Day 0; (iii) parasitemia at Day 3.25% than Day 0, and
recurrent parasitaemia after Day 4. Patients could be given less than
the full dose if they received rescue treatment or withdrew consent
from follow-up. Adequate Clinical and Parasitological Response
(ACPR) was defined as no parasitaemia until the end of the follow-up
without previously meeting any of the criteria for failure.
The efficacy was measured using Kaplan-Meier survival
analysis. We applied a statistical correction for cases where PCR
genotyping gave an indeterminate result or was unavailable,
computing adjusted quotients by determining the probability by
site and at any time of a parasite reappearance being either a
recrudescence or a new infection [18].
Secondary outcomes were:
i) The risks of recrudescence (reappearance of the same
genotype) in the DP groups compared to the comparator
groups (stratified by study), using the different lengths of
follow-up of each studies.
ii) The risks of recurrence (defined as recrudescence as above
and new infections) in the DP groups compared to the
comparator groups (stratified by study), using the different
length of follow-up of each studies.
iii) The risk of new infection (excluding recrudescences) in DP
groups compared to the comparator groups per study and
overall result (stratified by study) at Day 28.
The risks of treatment failure (i, ii, iii) were compared in
multivariate analysis (Cox regression models) individually and
overall by stratifying by site in an attempt to account for potential
statistical heterogeneity.
iv) The predictors of recrudescence or new infection or
recurrence by Day 28 were assessed by Cox regression
models. The covariates examined were: sex, age (continuous),
food absorption with the drug, anaemia on admission
(haematocrit ,30%), parasite count on admission (log
transformed), elevated temperature on admission (tempera-
ture measured by any method at $37.5u). As the age groups
were different between Africa (under 5 years old) and Asia
(children and adults), we conducted this part of analysis
separately for the 2 continents.
v) Gametocyte carriage
a. a. The predictors of gametocyte prevalence on admission were
measured using a logistic regression and controlling for site.
b. b. The time to clearance of gametocytes already present on
admission with data censored at the time of gametocyte
clearance was calculated based on the results of blood smears.
Within each study, the same sampling schedules were used for
all the patients, but between trials parasite counts were
performed at different times so any analysis was stratified by
site to account for these differences. For patients who cleared
gametocytaemia, time of the first negative count (followed by
further negative counts) was taken as time of clearance.
Differentials in gametocytes clearance were calculated using
Kaplan-Meier method using logrank test, stratified by site,
and a Cox regression model stratified by site measured the
risks of gametocytes carriage between treatment groups.
c. c. The predictors of gametocyte appearance during the follow-
up in patients without gametocytaemia on admission were
assessed by a Cox regression model stratified by site. The
presence of gametocytaemia after starting treatment was
analysed as a binary variable: the Mantel-Haenszel method
and the homogeneity test stratified by site were used to
estimate a combined odds ratio between treatments. One
positive gametocyte count at any time after treatment during
the follow-up period was enough to define gametocyte
carriage, while a complete set of negative counts during
follow-up was required to confirm no carriage.
d. d. Gametocyte carriage rates were measured in person-
gametocyte-weeks, using binary variable calculated within 42
days of follow-up. Person-gametocyte-weeks (PGW expressed
per 1000) were defined as the number of weeks in which blood
slides were positive for gametocyte divided by the total
number of weeks followed up in patients with gametocyte
results [19]. Mantel-Haenszel rate ratios (RR) weighted by site
were used to measure to the risks between treatment groups.
vi) Haematological changes were measured using the paired t-
test. Anaemia was defined as haematocrit ,30%, and
anaemia recovery during the follow-up by the time for the
haematocrit to reach 30% or more.
vii) Adverse events: defined as any sign, symptom, or disease that
was not present on admission and was associated with the use
of a medicinal product, whether or not it was considered as
related to the medicinal product. A serious adverse event was
defined as a sign or symptom that was fatal, life threatening or
required admission to hospital. Adverse events were stan-
dardised and expressed as an incidence density, in person-
days at risk within 28 days. The incidence rate ratio test was
used to compare the incidence of adverse events. We assumed
that young children (,5 years old) were unable to answer
questions about dizziness, nausea, headache, confusion,
numbness, hearing disturbance, tinnitus or visual disturbance.
viii) The effects of DP on P. vivax recurrences in the Asian trials
with longer follow-up (63 days) was calculated by censoring
the data at the time of P. vivax appearance (binary variable).
The predictors of P.vivax appearance were measured by using
Cox regression, and the incidence density of P. vivax
appearance was calculated in person-day.
Heterogeneity was assessed by the Cochran Q test, and I2 test.
Chi-square, Mann-Whitney, Kruskall-Wallis tests were used as
appropriate. Confidence intervals (CI) were measured at 95% by
the binomial distribution, or the Wilcoxon procedure, or the
Taylor series estimate as appropriate [20]. The statistical
programme used was STATA v10 (STATA corp.).
Results
Characteristics of included studies
A total of 3,547 patients were enrolled in six countries from 12
different sites between October 2003 and June 2006. Individually,
Dihydroartemisinin-Piperaquine
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the trials enrolled between 75 and 303 patients treated with DP
(total = 1,814), 1,475 patients treated with other ACTs, and 258 in
the non-ACT (AQ+SP) group (figure 1). The proportion of
patients lost to follow-up was ,10% in all the trials (4%, 110/
3,547 at Day 28).
Heterogeneity
In all the trials the methodological quality was high and the
randomisation sequence was computer-generated. All trials were
open label, and the basis for the sample size studied was provided
in all studies. In all studies, the primary treatment outcome was the
parasitological treatment failure. All trials reported data on
haemoglobin levels during follow-up, and recorded gametocyte
carriage at study enrolment and during follow-up. All studies
assessed adverse events and 10 different adverse events were
documented in all trials. Although there were differences in
geographical location, transmission intensity (ranging from low
and seasonal in Thailand to very high in the African trial settings),
age, treatment and supervision, heterogeneity between trials was
not significant (I2 test = 26%, P = 0.15, Cochran Q test for
heterogeneity), and regarded as low [21].
Baseline characteristics
The median age of the recruited patients was 13 years (range 1
to 65) (Table 1). Overall 32% of patients were under five years of
age, 28% were 5–14, and 40% were adults. In Asia, age
distributions were similar in Cambodia, and in Thailand. The
patients were younger in Laos and Myanmar, while in Rwanda
and Uganda only children were enrolled. There were no
differences detected in admission characteristics between DP
groups and comparator treatment groups, except for baseline
gametocytaemia in Myanmar [8].
Clinical recovery
Overall 54.6% of patients were febrile ($37.5uC) on admission.
This decreased to 8.8% at 24 h (i.e. median fever clearance
,24 hours) and 2.1% at 48 h. No difference was detected between
treatment groups. The median time for the spleen to be no longer
palpable was 14 days (range 1–42). There was no difference in the
time to resolution of splenomegaly between the treatment groups
(P = 0.70).
Parasitological efficacy
Of the 1,814 DP treated patients, 126 patients (6.9%) were lost
to follow-up by Day 28. Of the 221 patients with recurrent
infections, 9 cases had indeterminate PCR genotyping results, and
3 results were not available (lost samples). The results of
parasitological efficacy per study site are shown in table 2, the
number of patients followed-up, recurrent and recrudescent cases,
and the daily results by category of follow-up are shown for a
hypothetical cohort of 1000 persons with and without the PCR
correction (table 3). On Day 1 (24 hours after starting treatment),
31% (95%CI 29–34) of the patients had cleared their parasitae-
mia, on Day 2, 89% (95%CI 87–90), on Day 3, 98% (95%CI 97–
99). All patients had cleared their parasitaemia by Day 7.
Primary endpoint: parasitological efficacy at Day 28
In DP groups, the overall observed parasitological efficacy using
results from survival analysis at Day 28, corrected by PCR was
98.7% (95%CI 96.8–98.3). In children under 5 years old, the
corresponding efficacy was lower: 94.2% (95%CI 91.9–96.5,
P = 0.001). For the overall recurrence of P. falciparum parasitaemia
the corresponding results were 96.1% (95%CI 95.0–97.2) and
90.4% (95%CI 87.8–93.0) in children (P = 0.001).
Secondary endpoints
i) Risk of recrudescence for the full length of follow-up by
treatment group. Based on randomised comparisons by country
and using the full length of follow-up of the different trials, DP
recipients were at lower risk for a PCR confirmed failure compared
to MAS3 in Thailand (P = 0.001), AL in Uganda (P = 0.004), and
AQ+SP in Rwanda (P = 0.001)(figure 2, table S1). Overall, using
Figure 1. Note: DP; dihydroartemisinin-piperaquine, MAS3; mefloquine-artesunate, AQ+SP; amodiaquine+sulfadoxine-pyrimeth-
amine, AL; artemether-lumefantrine, AS+AQ; artesunate+amodiaquine, Pf; P. falciparum, loss; loss to follow-up, ACR; adequate
clinical response, ACT; artemisinin combination therapy.
doi:10.1371/journal.pone.0006358.g001
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Table 2. Dihydroartemisinin-piperaquine efficacy by country and site, Day 28, survival analysis (Kaplan-Meier).
Country and site Efficacy (%) Day 28 *
PCR uncorrected PCR corrected
Efficacy
Lower 95%
confidence
interval
Upper 95%
confidence
interval Efficacy
Lower 95%
confidence
interval
Upper 95%
confidence
interval
Uganda, site Apac, Day 28 89.0 84.8 93.2 98.0 92.9 98.8
Rwanda all sites, Day 28 88.4 83.7 91.8 95.2 91.6 97.3
Rwanda site MA 94.2 86.5 96.6 96.6 89.5 98.9
Rwanda site KI 97.3 89.4 99.3 97.3 89.4 99.3
Rwanda site RU 75.2 64.4 89.7 89.7 82.7 95.8
Thailand all sites, Day 28 98.2 97.2 99.2 99.5 98.0 99.7
Thailand site KT 97.0 95.1 98.9 99.0 95.9 99.3
Thailand site MT 100.0 98.7 100.0 100.0 98.7 100.0
Thailand site TR 97.8 91.1 98.5 100.0 97.8 100.0
Cambodia all sites, Day 28 98.6 94.3 99.1 99.1 95.5 99.3
Cambodia site AV 99.0 95.3 99.3 99.0 95.3 99.3
Cambodia site KV 98.1 90.6 98.6 99.1 95.4 99.3
Myanmar all sites, Day 28 98.1 97.2 99.0 99.3 95.4 99.4
site MN 98.4 93.8 100.0 100.0 97.2 100.0
site DB 97.4 93.8 98.8 99.5 98.1 99.9
Laos, Day 28 100.0 96.6 100.0 100.0 96.6 100.0
Total, Day 28 96.1 95.0 97.2 98.7 97.6 99.8
*Efficacy based on randomised trials was assessed by modified intent to treat analysis for recurrent and recrudescent cases. The Kaplan-Meier results were expressed as
percentages.
doi:10.1371/journal.pone.0006358.t002
Table 1. Trials baseline characteristics, patients receiving dihydroartemisinin-piperaquine.
Country characteristics on
admission Cambodia Laos Myanmar Rwanda Uganda Thailand Total
Total number of patients 228 13.4% 110 6.5% 327 19.2% 252 14.8% 211 12.4% 686 40.2% 1814 100%
Age, median in years (IQR; range) 21 (20;
2–65)
12 (17;
1–50)
7 (8;
1–42)
3 (2;
1–5)
2 (2;
1–9)
20 (20;
1–65)
12 (22;
1–65)
Age group 0–4 N, % 7 3.1% 19 17.4% 79 24.2% 248 98.4% 200 94.7% 31 4.5% 574 32%
5–14 N, % 61 26.6% 49 45.0% 191 58.4% 4 1.6% 11 5.3% 190 27.7% 506 28%
$15 N, % 161 70.3% 41 37.6% 57 17.4% 0 0.0% 464 67.7% 723 40%
Male N, % 160 69.9% 63 57.8% 165 50.5% 121 48.0% 97 46.0% 446 65.1% 1052 58%
Haematocrit (%) Mean
(SD)
35.5 (6.9) 35.0 (7.0) 27.8 (6.6) 31.5 (4.9) 28.5 (5.66) 37.3 (6.0) 33.9 (7.2)
Anaemia (,30% hct) N, % 40 17.5% 17 15.5% 205 62.7% 86 34.3% 87 41.2% 59 9.6% 407 26.6%
Geometric mean parasitaemia/uL 3331 18372 8864 29425 22788 9956 11247
(range) (40–173328) (3768–156623) (585–99502) (32–200000) (2080–192800) (66–221433) (32–221433)
Mixed infection N, % n-a n-a n-a n-a 40 12.2% n-a n-a n-a n-a 54 7.8% n-a
Gametocyte carriers N, % 17 7.4% 1 0.9% 137 41.9% 8 3.2% 41 19.4% 33 4.8% 237 13.1%
Splenomegaly N, % 54 23.6% 19 17.3% n-a n-a 25 10.0% n-a n-a 162 25.4% 260 21.2%
Hepatomegaly N, % 24 10.5% 12 10.9% n-a n-a 1 0.4% n-a n-a 121 19.0% 158 12.9%
Fever (T.37.5C) on admission N, % 153 67.1% 104 94.5% 148 45.4% 175 69.7% 211 100% 287 42.7% 867 54.6%
IQR; interquartile range.
n-a: no observation.
doi:10.1371/journal.pone.0006358.t001
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multivariate analysis stratified by site and controlling for age,
patients receiving DP had a lower risk of PCR confirmed treatment
recrudescence than with the comparator treatments (AHR = 0.32,
95%CI 0.21–0.48, P = 0.001).
ii) Risk of recurrence for the full length of follow-up, by
treatment group. Using multivariate analysis and the full
length of follow-up stratified by site and controlling for age and
anaemia, the overall risk of recurrence was lower in the DP groups
than in the comparator groups (AHR = 0.60, 95%CI 0.51–89,
P = 0.001)(figure 2). DP provided a better protective effect against
P. falciparum recurrence than its comparator groups in Rwanda;
compared to AQ+SP (P = 0.006) and AS+AQ (P = 0.006); to AL in
Uganda (P = 0.005); and MAS3 in Thailand (P = 0.016).
There was a longer interval from primary infection to
recurrence (suggesting a greater duration of suppressive prophy-
laxis) compared to MAS3 in Thailand (median: 49 days vs. 37
days, respectively, P = 0.001); in Uganda compared to AL (median
35 vs. 28 days, respectively, P = 0.001); in Rwanda compared to
AQ+SP (median 28 vs. 21 days, respectively, P = 0.035), but was
not different to AS+AQ (P = 0.23).
iii) Risk of new infections (PCR confirmed) by Day
28. At 28 days the risk of new infection was greater in
African compared to Asian settings (P = 0.001) reflecting the
higher transmission intensity. In these high transmission areas,
patients treated with DP were at lower risk for a new infection
within 28 days compared to AQ+SP (HR = 0.38, 95%CI 0.19–
0.76, P = 0.006), AS+AQ (HR = 0.42, 95%CI 0.21–0.86,
P = 0.018) in Rwanda and AL (HR = 0.38, 95%CI 0.22–0.65,
P = 0.001) in Uganda. Overall, in the multivariate analysis
stratified by site, DP had a greater post treatment prophylactic
effect (against new infections) at Day 28 against P. falciparum
compared to the other treatments (AHR = 0.47, 95%CI 0.33–
0.67, P = 0.001).
iv) Predictors of recrudescence, new infection, and
recurrence of P. falciparum in DP groups by Day 28. In
the DP groups, using multivariate analysis stratified by site at Day
28, age (as continuous variable) was the only predictor of
recurrence and recrudescence in Africa or Asia when analyzed
separately. In African children, younger patients (per 1 year
increase in age) were at higher risks for recurrence (AHR = 0.86,
95%CI 0.77–96, P = 0.006), and recrudescence (AHR = 0.80,
95%CI 0.68–96, P = 0.018), as well as in Asian patients
(AHR = 0.93, 95%CI 0.90–0.96, P = 0.001; and AHR = 0.81,
95%CI 0.73–0.89, P = 0.001, respectively).
No significant predictors of new infections were detected in
African children, but in Asian patients younger patients were at
higher risks for new infections (AHR = 0.96, 95%CI 0.93–0.99,
P = 0.025).
v) Gametocyte carriage. Admission pre-treatment
gametocytaemia was present in a median (range) of 6.1% (0.9–
41.9) of the patients. Using multivariate analysis in DP groups, and
controlling by site, younger patients, admission anaemia, and a
lower admission parasite count were related to a higher risk of
patent gametocytaemia (table 4).
Clearance of gametocytaemia was slower in DP groups than in
the comparators, overall and in individual sites. In Cambodia in
the DP treatment arm, 82(95%CI 55–94)% of patients presenting
with gametocytaemia still had gametocytaemia on Day 3
compared to only 27(7–54)% in the comparator arm. On Day
14 of the follow-up in Thailand 24(10–39)% in DP arm and 11(2–
30)% in the other arm, in Uganda 7.4(2.4–16)% in DP arm
compared to 1.8(0.3–13)% in the other arm, in Myanmar 31(23–
38)% in DP arm as compared to none in the comparator arm.
Overall, using multivariate analysis, the risk of gametocyte
carriage by Day 14 was lower in comparators than in DP groups
(P = 0.002, stratified by site)(figure 3, table S2).
Table 3. Pooled efficacy of dihydroartemisinin-piperaquine against falciparum malaria based on randomised trials assessed by
survival analysis (Kaplan-Meier).
Day group Followed up New infections
Recurrence (new
infection+recrudescence) Recrudescence
N N Quotient
Population free
of recurrence * N Quotient
Population
free of
recurrence * N Quotient **
population
free of
recrudescence *
0 1814 100.0 100.0 100.0
7 1797 2 0.0011 99.9 2 0.0011 99.9 0.0000 100.0
14 1779 2 0.0011 99.8 3 0.0017 99.7 1 0.0006 99.9
21 1758 8 0.0046 99.3 12 0.0068 99.0 4 0.0023 99.8
28 *** 1736 35 0.0206 97.3 51 0.0298 96.1 16 0.0104 98.7
35 1453 42 0.0298 94.4 52 0.0364 92.6 10 0.0069 98.1
42 **** 1388 47 0.0350 91.1 49 0.0359 89.3 2 0.0014 98.0
49 799 10 0.0127 89.9 11 0.0138 88.0 1 0.0013 97.8
56 777 22 0.0291 87.3 23 0.0300 85.4 1 0.0013 97.7
63 ***** 745 18 0.0248 85.1 18 0.0245 83.3 0 0.0000 97.7
Total 186 221 35
*Pooled efficacy based on randomised trials was assessed by intent to treat analysis for recurrent and recrudescent cases. The Kaplan-Meier analysis was computed for
an hypothetical cohort of 100 persons (the population free of disease per 100 is equivalent to efficacy expressed per 100). CI = confidence interval.
**Quotients adjusted for indeterminate cases.
***Endpoint Rwanda.
****Endpoint Laos, Uganda, Myanmar.
*****Endpoint Cambodia, Thailand.
doi:10.1371/journal.pone.0006358.t003
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Overall 178 (8.4%) out of 2125 patients presenting without
gametocytes developed gametocytaemia after starting treatment.
Recurrent parasitaemia as well as anaemia on admission were
associated with gametocyte appearance (Table 4). There were no
significant overall differences in the risk of developing gametocy-
taemia during follow-up between DP and all comparator arms
(Mantel-Haenszel OR = 1.02 [95%CI 0.75–1.40], P = 0.89;
P = 0.035 for homogeneity between studies). However, there were
significant differences in appearance of gametocytes in 3 Asian
countries (Cambodia, Myanmar, Thailand) between DP and
MAS3 (Mantel-Haenszel OR = 1.89, 95%CI 1.23–2.91,
P = 0.003; P = 0.643 for homogeneity between studies). Including
the Laos results, which only recorded if the patients had
gametocyte after admission as a sole binary variable, the
proportion of patients with gametocyte appearance within 42
days was higher in DP groups (6.5%, 76/1164) compared to
MAS3 groups (4.0%, 35/873) (OR = 1.96, 95%CI 1.28–3.09,
P = 0.002, Mantel-Haenszel weighted by site)(figure 4).
In Cambodia, Myanmar, and Thailand, the overall gametocyte
carriage rate within 42 days was greater in the DP (56/1000 PGW,
260/4675, 95%CI 49–62) compared to MAS3 groups (36/1000
PGW, 100/2772, 95%CI 29–43)(RR = 1.36, 95%CI 1.06–1.76,
P = 0.017, Mantel-Haenszel weighted by site). In patients without
gametocytaemia on admission and who developed gametocytae-
mia during the follow-up, the carriage rate was also greater with
DP (11/1000 PGW) than MAS3 (6/1000 PGW)(RR = 2.88,
95%CI 1.51–6.28, P = 0.001, Mantel-Haenszel weighted by site).
When using available data (from Thailand, Cambodia,
Myanmar, and Uganda) there was no relationship between the
dose of DHA actually received by the patient and the proportion
of patients remaining with gametocytaemia on Day 14 (P = 0.382).
vi) Haematological changes. On admission, 537 out of
1,797 (29.9%) DP recipients with available data were anaemic
(Hct,30%). Of these 29.8% (74/537) had severe anaemia
(Hct,20%). Using multivariate analysis, anaemia on admission
was strongly associated with age and varied by country (Table 1).
Children under 15 y were at higher risk for anaemia compared to
adults as well as patients from Cambodia, Uganda, and Myanmar
compared to Thailand (P = 0.001, for all comparisons). By Day 28,
55% (162/293) of the anaemic patients had recovered from
anemia and 2.8% (24/851) who were not anaemic on admission
became anaemic. Overall, in anaemic patients, the median time to
recovery (defined as haematocrit$30%) ranged from 7 to 42 days.
On Day 42, the prevalence of anaemia was 3.4% (34/985).
There were no treatment differences in the development of
anaemia.
In Cambodia, Laos, Myanmar, Thailand, there was a relative
mean paired transient decline of 6.3% (95%CI 5.7–7.3) in
haematocrit from admission to Day 7 in DP groups. No difference
was detected compared to the MAS3 group. By contrast, in
Rwanda, between Day 0 and Day 14, the relative mean paired
haematocrit difference was significantly higher in the AS+AQ
group (+10%, 95%CI 8–11) compared to the DP group (+6%,
95%CI 4–8)(P = 0.021). In Uganda, patients treated with DP
(+20%, 95%CI 16–24) had a higher relative paired mean increase
in haemoglobin levels on Day 42 compared to AL group (+16%,
95%CI 12–20, P = 0.049).
vii) Drug vomiting, incidence of adverse events, number
of adverse events, and death.. Overall, vomiting on
admission and before treatment administration was a risk factor
for vomiting the first dose of DP (OR = 6.1, 95%CI 3.2–11.7) and
for vomiting DP treatment over the three days (OR = 4.6, 95%CI
2.7–7.7). This was similar in every country. In patients who did not
present with vomiting on admission, the overall incidence of early
vomiting (defined as vomiting the drug within 1 hour after intake)
DP was low; 1.7% (21/1,231) on Day 0. Over the 3 days of
treatment, the overall incidence rate of early vomiting ranged from
3.2 (95%CI 2.1–4.8)% in Thailand to 9.9 (95%CI 6.8–14.4)% in
Rwanda (Table 5). In DP groups, drug vomiting was more
frequent in Rwanda than all other countries (P = 0.001) and was
related to age: the 0–4 y age group (OR = 8.2, 95%CI 3.2–21.3),
and the 5–14 y age group (OR = 3.9, 95%CI 1.9–8.1) were at
higher risk compared to adults. In Rwanda, the incidence of
overall vomiting DP was not different to that after AS+AQ
(11.5%, P = 0.565), but the risk was much lower than with AQ+SP
(19.5%, P = 0.002). No difference in the incidence of early
vomiting after drug treatment was observed between DP and
MAS3 on Day 0 (3.2%, and 2.4%, respectively, P = 0.400), or
overall (3.7%, and 4.2%, respectively, P = 0.671).
Figure 2. Note: HR; hazard ratio, CI; confidence interval. DP;
dihydroartemisinin-piperaquine, MAS3; mefloquine-artesunate, AQ+SP;
amodiaquine+sulfadoxine-pyrimethamine, AL; artemether-lumefan-
trine, AS+AQ; artesunate+amodiaquine. NC: not computable because
of no recrudescent cases. *Overall number of failures does not add up
because two comparators were used in Rwanda. Note: the forest plot
represents the risk of parasite reappearance (PCR corrected; i.e.
recrudescence, and not corrected i.e. recrudescence+new infection) of
DP versus comparators in comparative studies. Groups size are
equivalent except in Thailand where the DP group was twice as large
(N= 686). Endpoints were assessed on Day 28 in Rwanda, Day 42 in
Laos, Myanmar, and Uganda, and Day 63 in Cambodia, and Thailand.
Overall results were stratified by site, and drugs. The size of the boxes is
proportional to the number of patients included and thus to the overall
effect. The diamond represents the overall hazard ratio and 95% CI.
doi:10.1371/journal.pone.0006358.g002
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We examined the incidence and prevalence of 24 other different
adverse events (apart from early vomiting) in 1,267 individuals
using available records from DP groups in five countries and 9
different sites. It was not possible to calculate the adverse events
duration in Laos, and Uganda. In the remaining DP groups, the
five most commonly reported adverse events by Day 28 were
23.3% for headache, 17.0% for dizziness, 13.8% for sleep
disturbance, 11.6% for anorexia, 10.5% for nausea (table 6).
Hypersensitivity reactions including urticaria were reported in 4
patients in Thailand (0.6%, 4/686, 95%CI 0.2–1.5) [6]. The
following adverse events: muscle pain, hearing disturbances,
itching, nightmares, visual disturbances, dyspnoea, numbness,
skin rash, agitation and confusion, were all reported in less than
5% of cases. The maximum point prevalence rates of the adverse
events all occurred on Day 1. Day 1 and Day 2 captured 54% and
the first week captured 70% of the reported adverse event
incidence.
In the Asian trials, the only adverse event that was significantly
more frequent in DP treated patients compared to the MAS3
group was diarrhoea in all age groups (children: 36% 310/852 vs.
17% 108/625, OR = 2.74, 95%CI 2.13–3.51; adults: 46% 248/
543 vs. 21% 83/390, OR = 3.11, 95%CI 2.31–4.18, respectively,
P = 0.001 for both comparisons, figure 5, table S3). Regarding
other gastro-intestinal adverse events, DP was significantly better
tolerated than AS+AQ, AS+SP, or MAS3 (P,0.040 for all
comparisons) but was not different compared to AL (only for late
vomiting). In adults the risk of nightmare (P = 0.028) and sleep
disturbances (P = 0.003) was lower in the DP group than in the
MAS3 group. The risk of dermatological events (P = 0.002),
dizziness, palpitation, and muscle pain in all ages was also lower
than in the MAS3 group (P,0.010 for all comparisons). The risks
of hearing disturbance (tinnitus, or hearing problems) in adults
treated with MAS3 was greater than in the DP group (P = 0.001).
The frequency of patients treated with DP and reporting at least
one of the 24 adverse events analyzed was 57.2% (840/1,468,
95%CI 54.7–59.8); among them 38% reported one, and 26% two
adverse events (without excluding patients under 5). The total
number of adverse events reported per patient was higher in older
patients (P = 0.001) and in anaemic patients on admission
(P = 0.020 after correcting for age).
The incidence of adverse events was significantly lower in DP
recipients compared to MAS3 recipients (on average by 259%,
95%CI 228 to 290%, P = 0.001). More patients treated with
MAS3 reported two or more AEs (67%, 454/675, P = 0.034). In
Rwanda, the risk of having any adverse event was higher in the
AQ+SP group (OR = 2.19, 95%CI 1.35–3.57) and in the AS+AQ
group (OR = 1.90, 95%CI 1.15–3.12) compared to the DP group.
No differences were detected in Uganda in the AL group
compared to the DP group.
A child from Rwanda had a seizure and received a rescue
treatment. Overall, 5 deaths occurred in DP groups, all of which
were considered to be unrelated to the treatment, except in
Thailand where a 43-year-old woman who died from severe
Table 4. Predictors of patent gametocytaemia, and gametocyte appearance, dihydroartemisinin-piperaquine groups.
Independent variables Gametocyte on admission Gametocyte appearance
Age continuous AOR=0.97, 95%CI 0.95–0.98, p = 0.001
Anaemia (ref: no anaemia) AOR =1.83, 95%CI 1.43–2.34, p = 0.001
Parasite count (continuous) AOR =0.69, 95%CI 0.58–0.82, p = 0.001
Model 1 for recurrence
Anemia on admission AHR= 2.71, 95%CI 1.56–4.73, p = 0.001
Recurrence during follow-up AHR= 2.66, 95%CI 1.32–5.39, p = 0.001
Model 2 for recrudescence
Anemia on admission AHR= 2.83, 95%CI 2.61–8.66, p = 0.001
Recrudescence during follow-up AHR= 2.90, 95%CI 0.68–12.45, p = 0.152
Note: Age was per 1 year increase in age, and parasite count was per 1 unit increase in the log transformed parasite density. AOR; adjusted odds ratio. AHR; adjusted
hazard ratio. CI; confidence interval.
doi:10.1371/journal.pone.0006358.t004
Figure 3. Note: the forest plot represents the risk of clearing
gametocytes comparing DP versus comparator drugs in
randomised studies. The endpoint was assessed at Day 14. Overall
result was stratified by site. The size of boxes is proportional to the
number of patients included and thus to the overall effect. The
diamond represents the overall hazard ratio and 95% CI.
doi:10.1371/journal.pone.0006358.g003
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malaria the day after entering the study, which might have been
related to a lack of efficacy of the drug. In Thailand, there were
another 2 deaths: a 13-year-old girl who died on Day 7 from
probable bacterial sepsis, and a 21 year old male who died on Day
28 from gunshot wounds. In Laos, a two year old child died on
Day 37 from cerebral malaria after probable reinfection. In
Myanmar, one 11-year-old child died after developing fever on
Day 20 and had generalized seizures the next morning (Day 21).
The malaria smear was negative. In the comparator groups, one
death occurred in MAS3 groups in Thailand involving a malaria-
smear negative 13-year-old boy, who was clinically well by the
third day of treatment. He was reported to have deteriorated
rapidly with worsening abdominal pain and distension, jaundice,
and anuria, and he died within a few hours.
viii) Plasmodium vivax and other species appearing
during the follow-up period. No difference was detected
between DP groups and the comparator (mefloquine-artesunate)
in P. vivax recurrence rates (P.0.05 for all comparisons). In
Cambodia, Laos, Myanmar, and Thailand, 265 patients receiving
DP (28.8/100 person-days within 63 days) had P. vivax
parasitaemia detected during the follow-up (figure 6). The
median (range) time to the P. vivax parasitaemia was 49 (14–63)
days compared with 49 (28–63) days, in MAS3 groups. Patients
with P. vivax on admission (mixed infections) were at higher risk of
having a second P. vivax episode during the follow-up (HR = 1.70,
95%CI 1.15–2.51, P = 0.008). Children were at increased risk of P.
vivax recurrence when compared to adults; 0–4 age group
(HR = 2.85, 95%CI 1.81–4.48, P = 0.001) and the 5–14 age
group (HR = 1.43, 95%CI 1.05–1.94, P = 0.024). In patients who
had mixed infections on admission, the median time to P. vivax
recurrence was 42 days (7–63), significantly shorter than in
patients presenting with a P. falciparum monoinfection: 49 (16–70)
days, (P = 0.029). In Uganda patients treated with DP had a lower
risk of recurrent parasitaemia due to P. malariae and P. ovale species
compared to patients treated with AL (5.2% versus 0.9%,
P = 0.001)[10].
Discussion
Since initial deployment in 1994 of the mefloquine-artesunate
(MAS3) combination to treat P. falciparum malaria along the Thai-
Myanmar border, there has been increasing use of ACTs
throughout the malaria affected world. Dihydroartemisinin-
piperaquine (DP) is a relatively new and very promising fixed
dose ACT which has been extensively evaluated in the past few
years. This analysis of 3,547 patients (1,814 of whom received DP)
in randomized comparative clinical trials includes 7 of the 22
published studies (until December 2008), but is broadly represen-
Figure 4. Note: DP; Dihydroartemisinin-piperaquine, MAS3; mefloquine-artesunate.
doi:10.1371/journal.pone.0006358.g004
Table 5. Early vomiting (,one hour) after treatment administration, dihydroartemisinin-piperaquine groups.
Country Daily incidence Total incidence 95% confidence interval N
Day 0 Day 1 Day 2
Myanmar 2.1% 1.2% 0.6% 4.0% 2.3%–6.8% 13/327
Cambodia 4.8% 1.3% 0.0% 5.2% 3.0%–9.1% 12/228
Rwanda 6.7% 2.4% 2.8% 9.9% 6.8%–14.4% 25/252
Thailand 2.6% 0.6% 0.1% 3.2% 2.1%–4.8% 22/686
Total 3.5% 1.1% 0.5% 4.8% 3.7%–5.9% 72/1495
doi:10.1371/journal.pone.0006358.t005
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tative as it comprises a wide patient age range and derives from
areas of widely differing intensity of malaria transmission. It is the
first individual patient data set compiled prospectively, based on
randomized comparisons in studies of generally similar overall
design. It includes half (49%, 1,814/3,678) of all the patients
treated with DP in published clinical trials with parasite
genotyping corrected results and reports 43% (1,814/4,212) of
all patients included in published studies to date.
To present the results of this analysis of individual patient data we
have used a method similar to that used for a meta-analysis of trials
(for instance in Cochrane’s review) with graphical representation of
risks, recommended for communicating in medical research [22].
Compared to a ‘‘conventional’’ meta-analysis from published
studies, the analysis of individual patient level data increases
statistical power by facilitating analytical practice, and enables
standardized estimates of drug efficacy across different studies.
In the 12 different African and Asian sites with varying levels of
background antimalarial drug resistance, DP was well tolerated
and highly efficacious. Like all ACTs DP produces rapid
therapeutic responses with swift resolution of symptoms and fever
and clearance of parasitaemia. Efficacy (PCR corrected) exceeded
96% in all sites except one in Rwanda, where no food was co-
administered with the drug. Treatment with DP was associated
with lower risks of overall recurrence (P = 0.001), recrudescence
(P = 0.001), and new infections (P = 0.001) compared with the
comparator drugs. The superiority of DP was demonstrated in
Rwanda, Uganda and Thailand against the local current first-line
treatments. This excellent efficacy and tolerability profile suggests
that DP could be considered as a potential alternative first-line
antimalarial treatment. This result based on studies of 1,814 adults
and children who received antimalarial treatment with DP,
contrasts with the recently reported finding of a study of 100
young children in Papua New Guinea [23]. DP was not
administered with food in that study, a factor that could contribute
to lower oral piperaquine absorption, and reduce therapeutic
efficacy [24]. High levels of chloroquine resistance were
considered a possible explanatory factor, although levels of
chloroquine resistance were also very high in the study sites in
this multi-center analysis. PCR corrected efficacy in adjacent
Papua with DP treatment was over 95%, although this trial
enrolled adults and children [25]. The reasons for lower efficacy in
Rukara, Rwanda are unclear but consistent with the lower efficacy
of other ACTs such as amodiaquine-artesunate at this site
compared to other Rwandan sites [26] and could also be related
with the fact that DP was not administered with food. The
superior protective effect of DP against reinfection and suppression
of vivax relapses compared with the other drugs presumably
results from the long terminal half-life of piperaquine. Suppression
of reinfection provides longer disease free intervals but at the
expense of increased selection pressure for resistance to piper-
aquine compared with more rapidly eliminated partner drugs.
DP was less potent than mefloquine–artesunate in suppressing
gametocytaemia. Similar results were also observed in Kenya in
comparison with AL [27], and in Peru compared to MAS3 [28].
Taken together these results indicate that the reduction in
gametocytaemia, an important pharmacodynamic advantage of
ACTs, is less pronounced with DP than with other ACTs. This
could be related to the relatively lower dose of DHA (2.5 mg/kg/
day) compared to the dose of artesunate in the comparators
(4 mg/kg/day). But in our analysis we found no relationship
between the dose of DHA received by the patients in the DP arms
and the clearance of gametocytaemia. Prolonged gametocytemia
has been proposed as an early sign of the emergence of drug
resistance [29]. This might be a concern given the poorer
gametocytocidal effects of DP. However the gametocyte carriage
rate remained low, and the gametocyte clearance was fast. A
relatively few patients had detectable gametocytemia during the
studies, which reflects the potent gametocytocidal properties of the
artemisinin derivatives.
DP was effective in treating non-P. falciparum species co-
infections. Unlike P. falciparum infections, recurrence of P. vivax
(either relapses or failures) cannot be reliably distinguished from a
new infection [30]. Mixed infections are common. Approximately
one third of acute falciparum malaria infections in the South-East
Table 6. Adverse event incidence density and prevalence rates, dihydroartemisinin-piperaquine groups.
Adverse event Adverse event cumulative incidence density over 28 days
Incidence
within the
first week* Adverse event maximum prevalence
Number of patients without
the symptom on admission %
Lower
95%CI
Upper
95%CI Day % Lower 95%CI
Upper
95%CI
Headache 124 23.3% 15.4% 31.2% 74% Day 1 9.9% 5.8% 17.0%
Dizziness 457 19.3% 15.3% 23.2% 88% Day 1 11.6% 8.5% 14.8%
Sleeping problem 811 18.4% 15.0% 21.7% 83% Day 1 6.3% 4.8% 8.2%
Anorexia 521 16.7% 13.4% 19.9% 85% Day 1 10.3% 7.7% 13.0%
Fatigue 628 15.0% 12.4% 18.1% 82% Day 1 7.7% 5.9% 10.1%
Nausea 628 13.6% 10.8% 16.5% 83% Day 1 8.7% 6.4% 11.0%
Joint pain 451 10.0% 7.6% 13.3% 63% Day 1 4.7% 3.1% 7.2%
Abdominal pain 1040 9.6% 7.8% 11.4% 76% Day 1 4.7% 3.4% 6.0%
Diarrhoea 1204 9.2% 7.5% 10.9% 84% Day 1 4.8% 3.6% 6.1%
Late vomiting 1083 7.1% 5.5% 8.7% 86% Day 1 4.7% 3.4% 6.0%
Palpitations 753 6.7% 5.1% 8.8% 82% Day 1 3.2% 2.2% 4.8%
Hearing disturbance 971 6.3% 4.5% 8.1% 68% Day 1 2.4% 1.3% 3.5%
CI; confidence interval.
*The incidence within the first week is the proportion of cases occurring in the first week divided by the total number of cases within 28 days for each adverse event.
doi:10.1371/journal.pone.0006358.t006
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Asian region are followed by a vivax malaria relapse. In trials with
63 days follow-up the recurrent episode of vivax malaria in
patients with mixed infections on admission occurred slightly
earlier (6 weeks) than new vivax appearances in patients with a
falciparum mono-infection (7 weeks). Thus, the first relapse is
suppressed by DP, comparable to the effect of chloroquine on
sensitive P. vivax strains [31].
The higher risk of treatment failure in children treated with DP
compared with adults is similar to the pattern seen with other
antimalarial drugs, and presumably results both from lower
immunity and lower blood piperaquine concentrations. The
shorter time to P. vivax reappearance in children would also
support a pharmacokinetic explanation. The Day 7 piperaquine
level is a useful measure of drug exposure. Young children have
lower piperaquine levels on Day 7 and higher treatment failure
rates than older children and adults [4,25]. In a recently reported
population pharmacokinetic study from Thailand, there were
therapeutically relevant pharmacokinetic differences between
different age groups. Children had a smaller central volume of
distribution, a shorter distribution half-life (t1/2, a), and a more
rapid fall in initial PQ plasma concentrations compared to the
population mean profile [4]. Studies indicated lower plasma
piperaquine concentration in children compared to adults in
Papua, Indonesia [25] and higher clearance in children in
Vietnam [32]. Taken together these data argue for higher weight
adjusted doses in children compared with adults. This would also
Figure 5. Note: the forest plot represents the risk of adverse event appearance after the start of dihydroartemisinin-piperaquine
treatment in children (,15 y) and adults who did not present this symptom on admission versus comparators in comparative
studies. The size of boxes is proportional to the number of patients included. 95% confidence intervals (CI) are calculated for the odds ratio (OR).
doi:10.1371/journal.pone.0006358.g005
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have the advantage of providing a larger dose of dihydroarte-
misinin. Further studies in young children to optimize the dose of
DP are needed.
The risk of early vomiting of DP was lower than following
AQ+SP in Rwanda (P = 0.001). No differences were observed with
the other comparator treatments. Early vomiting was more
frequent in young children, although it was not a risk factor for
treatment failure, presumably because these children were re-
dosed successfully after vomiting the drug.
The DP safety profile has been excellent in all published series.
The overall safety analysis showed that the risk of the most
common adverse events was significantly lower following DP
treatment than in the comparator arms in both children (,15
years old) and adults. Adverse events were often related to the
disease itself (particularly neurological and gastro-intestinal AEs),
although diarrhea was approximately twice as common following
DP than with MAS3.
The use of common protocols for data collection to assess
antimalarial drug efficacy and tolerability allows combination of
these data into larger international databases which can give us
more information on the safety and efficacy of these drugs in
different patient groups [33]. While methods for assessing
antimalarial drug efficacy are well standardized there is little
uniformity in safety reporting in antimalarial drug studies, a
problem which needs to be addressed.
DP is not yet recognized internationally and its use has been
limited by its regulatory status. The formulation used in the trials
was donated by Holley and manufactured according to Chinese
SFDA Good Manufacturing Practice (GMP) standards. Never-
theless, differences in efficacy might be related to the variability in
the composition of the study drug.
This antimalarial combination is currently under evaluation
by the WHO pre-qualification process. DP is clearly an
important new antimalarial drug. It is well tolerated, highly
effective and safe. The higher rates of gametocytaemia
compared with other ACTs and lower piperaquine levels early
in the terminal elimination phase observed in children suggest
that dosage may have to be increased in this important patient
group.
Supporting Information
Table S1 (for figure 2): Recurrences (PCR uncorrected) and
recrudescences (PCR corrected) comparing the risks in the
dihydroartemisinin-piperaquine group versus the comparator
arms by drug and country of study. *Overall number of failures
does not add up because two comparators were used in Rwanda.
Note: the forest plot represents the risk of parasite reappearance
(PCR corrected; i.e. recrudescence, and not corrected i.e.
recrudescence+novel infection) of DP versus comparators in
comparative studies. Groups size are equivalent except in
Thailand where the DP group was twice as large (N = 686).
Endpoints were assessed on Day 28 in Rwanda, Day 42 in Laos,
Myanmar, and Uganda, and Day 63 in Cambodia, and
Thailand. Overall results were stratified by site, and drugs.
HR: hazard ratio
Found at: doi:10.1371/journal.pone.0006358.s001 (0.07 MB
DOC)
Table S2 (for figure 3): Risks of clearing gametocytaemia by Day
14 in patients with gametocytaemia on admission, dihydroarte-
misinin-piperaquine (DP) group versus comparators arms by drug
and country of study. HR; hazard ratio, CI; confidence interval.
(NC): not computable because of the day of clearance not
available.
Found at: doi:10.1371/journal.pone.0006358.s002 (0.05 MB
DOC)
Table S3 (for figure 5): Day 28 adverse event risks for
‘treatment’ DP versus controls (comparators)Note: The risk of
adverse event appearance after the start of dihydroartemisinin-
piperaquine treatment in children (,15 y) and adults who did not
present this symptom on admission versus comparators in
comparative studies. 95% confidence intervals (CI) are calculated
for the odds ratio (OR)
Figure 6. P.vivax cumulative incidence density, dyhydroartemisinin-piperaquine treatment groups. Patients receiving DP in Cambodia,
Laos, Myanmar, and Thailand who had P. vivax parasitaemia detected during the follow-up.
doi:10.1371/journal.pone.0006358.g006
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Found at: doi:10.1371/journal.pone.0006358.s003 (0.12 MB
DOC)
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